Open AccessLong‐term outcomes of catheter ablation of ventricular tachycardia in patients with structural heart disease
Author(s) -
Goya Masahiko,
Fukunaga Masato,
Hiroshima Kenichi,
Hayashi Kentaro,
Makihara Yu,
Nagashima Michio,
An Yoshimori,
Ohe Seiji,
Yamashita Kennosuke,
Ando Kenji,
Yokoi Hiroyoshi,
Iwabuchi Masashi,
Katayama Kouji,
Ito Tomoaki,
Niu Harushi
Publication year - 2015
Publication title -
journal of arrhythmia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 21
eISSN - 1883-2148
pISSN - 1880-4276
DOI - 10.1016/j.joa.2014.06.001
Subject(s) - medicine , cardiology , catheter ablation , ventricular tachycardia , ablation , myocardial infarction , clinical endpoint , ventricular fibrillation , heart disease , cardiomyopathy , heart failure , randomized controlled trial
Background Catheter ablation of ventricular tachycardia (VT) is feasible. However, the long‐term outcomes for different underlying diseases have not been well defined. Methods Eighty‐eight consecutive patients who underwent catheter ablation of VT using a three‐dimensional mapping system were analyzed. The primary endpoint was any VT or ventricular fibrillation (VF) recurrence. Secondary endpoints were a composite of death or any VT/VF recurrence. Underlying heart diseases were remote myocardial infarction (remote MI) in 51 patients and non‐ischemic cardiomyopathy in 37 (arrhythmogenic right ventricular cardiomyopathy [ARVC] in 18 patients, and dilated cardiomyopathy [NIDCM] in 19). Results Acute success was achieved in 82 of 88 (93%) patients. During a follow‐up period of 39.2±4.6 months, VT recurred in 26 of 87 (30%), and VT/VF recurrence or death occurred in 39 of 87 (45%) patients. ARVC had better outcomes than NIDCM for the primary ( p <0.05) and secondary endpoints ( p <0.05). Remote MI‐VT revealed a midrange outcome. Conclusions The long‐term outcomes after catheter ablation of VT varied according to the underlying heart disease. ARVC‐VT ablation was associated with better long‐term prognosis than NIDCM. Remote MI‐VT demonstrated a midrange outcome.